Table 2.
Univariate and multivariate analysis for disease-free survival
| UVA | MVA | |||
|---|---|---|---|---|
| HR (95% CI) |
p-Value | HR (95% CI) |
p-Value | |
|
Sex male (n = 45) female (n = 22) |
1.86 (0.39–8.95) |
0.44 | − | − |
|
Age >65 (n = 25) ≤65 (n = 42) |
0.56 (0.12–2.69) |
0.47 | − | − |
|
ypN stage N+ (n = 20) N− (n = 47) |
1.21 (0.30–4.84) |
0.79 | − | − |
|
Dworak TRG 3–4 (n = 28) 0–2 (n = 39) |
0.74 (0.18–2.95) |
0.67 | − | − |
|
Histologic grade 3 (n = 7) 1 + 2 (n = 58) |
0.20 (0.002–17.98) |
0.49 | − | − |
|
Adjuvant chemotherapy yes (n = 35) no (n = 30) |
0.88 (0.22–3.52) |
0.86 | − | − |
|
PD-L1 TPS pre-CRT >1% (n = 48) ≤1% (n = 17) |
0.40 (0.11–1.50) |
0.18 | − | − |
|
NAR score intermediate/high (n = 56) low (n = 11) |
27.20 (0.02–43,658.20) |
0.38 |
− |
− |
95% CI: 95% confidence interval; CRT: chemoradiotherapy; HR: hazard ratio; MVA: multivariate analysis; NAR score: neoadjuvant rectal score; PD-L1: programmed death-ligand 1; TPS: tumor proportion score; TRG: tumor regression grade; UVA: univariate analysis.